DE69910411D1 - Medikament zur behandlung von infektionen - Google Patents

Medikament zur behandlung von infektionen

Info

Publication number
DE69910411D1
DE69910411D1 DE69910411T DE69910411T DE69910411D1 DE 69910411 D1 DE69910411 D1 DE 69910411D1 DE 69910411 T DE69910411 T DE 69910411T DE 69910411 T DE69910411 T DE 69910411T DE 69910411 D1 DE69910411 D1 DE 69910411D1
Authority
DE
Germany
Prior art keywords
organism
ycf
inhibitor
growth
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69910411T
Other languages
English (en)
Other versions
DE69910411T2 (de
Inventor
John Wilson
William Mullineaux
Elizabeth Law
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of DE69910411D1 publication Critical patent/DE69910411D1/de
Publication of DE69910411T2 publication Critical patent/DE69910411T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69910411T 1998-09-22 1999-09-22 Medikament zur behandlung von infektionen Expired - Fee Related DE69910411T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9820658 1998-09-22
GBGB9820658.4A GB9820658D0 (en) 1998-09-22 1998-09-22 Treatment of infection
PCT/GB1999/003180 WO2000016758A2 (en) 1998-09-22 1999-09-22 Treatment of infection

Publications (2)

Publication Number Publication Date
DE69910411D1 true DE69910411D1 (de) 2003-09-18
DE69910411T2 DE69910411T2 (de) 2004-06-24

Family

ID=10839286

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69910411T Expired - Fee Related DE69910411T2 (de) 1998-09-22 1999-09-22 Medikament zur behandlung von infektionen

Country Status (6)

Country Link
EP (1) EP1115386B1 (de)
AT (1) ATE246921T1 (de)
AU (1) AU6212999A (de)
DE (1) DE69910411T2 (de)
GB (1) GB9820658D0 (de)
WO (1) WO2000016758A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992620A1 (de) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamid-Pyrimidon-Derivate zur Behandlung von neurodegenerativen Krankheiten

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035057A1 (en) * 1997-02-06 1998-08-13 The National University Of Singapore Diagnosis of plasmodium infection by analysis of extrachromosomal genetic material

Also Published As

Publication number Publication date
DE69910411T2 (de) 2004-06-24
WO2000016758A2 (en) 2000-03-30
GB9820658D0 (en) 1998-11-18
ATE246921T1 (de) 2003-08-15
AU6212999A (en) 2000-04-10
WO2000016758A3 (en) 2000-07-20
EP1115386A2 (de) 2001-07-18
EP1115386B1 (de) 2003-08-13

Similar Documents

Publication Publication Date Title
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
BR9916785A (pt) Tratamento de asma com inibidores mek
BR0007532A (pt) Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
ATE343415T1 (de) Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69522702D1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
DE69910411D1 (de) Medikament zur behandlung von infektionen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
DE602004016841D1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE60108775T8 (de) Methode zur behandlung von schlaganfall
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee